| |
| |
|
| Insider
Information: |
Pops Richard F |
| Relationship: |
Director |
| City: |
Cambridge |
| State: |
MA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
4 |
|
| Direct
Shares |
1,301,687 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$38,585,989 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
1,301,687 |
|
|
| Total
Value |
$38,585,989 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Neurocrine Biosciences Inc |
NBIX |
Director |
2024-03-13 |
29,512 |
2005-11-23 |
0 |
Premium* |
|
|
Alkermes Plc |
ALKS |
Director and CEO, Alke... |
2024-02-08 |
1,179,675 |
2011-09-16 |
0 |
Premium* |
|
|
Epizyme, Inc. |
EPZM |
Director |
2013-05-30 |
60,000 |
|
0 |
Premium* |
|
|
Acceleron Pharma Inc |
XLRN |
Director |
2019-01-25 |
32,500 |
|
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
257 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 7 of 11
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| ALKS |
Alkermes Plc |
Director and CEO, Alkermes plc |
• • – |
2018-02-17 |
4 |
D |
$67.26 |
$173,598 |
D/D |
(2,581) |
643,855 |
0 |
- |
|
| ALKS |
Alkermes Plc |
Director and CEO, Alkermes plc |
• • – |
2018-02-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,750 |
646,436 |
0 |
- |
|
| ALKS |
Alkermes Plc |
Director and CEO, Alkermes plc |
• • – |
2018-03-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
17,500 |
666,910 |
0 |
- |
|
| ALKS |
Alkermes Plc |
Director and CEO, Alkermes plc |
• • – |
2018-03-01 |
4 |
D |
$57.41 |
$446,592 |
D/D |
(7,779) |
659,131 |
0 |
- |
|
| XLRN |
Acceleron Pharma Inc |
Director |
– • – |
2018-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
1,250 |
31,250 |
0 |
- |
|
| ALKS |
Alkermes Plc |
Director and CEO, Alkermes plc |
• • – |
2018-03-03 |
4 |
D |
$60.05 |
$347,029 |
D/D |
(5,779) |
666,352 |
0 |
- |
|
| ALKS |
Alkermes Plc |
Director and CEO, Alkermes plc |
• • – |
2018-03-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
13,000 |
672,131 |
0 |
- |
|
| XLRN |
Acceleron Pharma Inc |
Director |
– • – |
2018-03-06 |
4 |
S |
$41.34 |
$1,553,094 |
D/D |
(37,500) |
31,250 |
0 |
- |
|
| XLRN |
Acceleron Pharma Inc |
Director |
– • – |
2018-03-06 |
4 |
OE |
$5.08 |
$190,500 |
D/D |
37,500 |
68,750 |
0 |
- |
|
| NBIX |
Neurocrine Biosciences In... |
Director |
– • – |
2018-05-01 |
4 |
OE |
$7.05 |
$105,750 |
D/D |
15,000 |
44,512 |
0 |
- |
|
| ALKS |
Alkermes Plc |
Director and CEO, Alkermes plc |
• • – |
2018-05-01 |
4 |
OE |
$12.29 |
$614,500 |
D/D |
50,000 |
716,352 |
0 |
- |
|
| ALKS |
Alkermes Plc |
Director and CEO, Alkermes plc |
• • – |
2018-05-01 |
4 |
AS |
$44.01 |
$2,201,167 |
D/D |
(50,000) |
666,352 |
0 |
- |
|
| NBIX |
Neurocrine Biosciences In... |
Director |
– • – |
2018-05-01 |
4 |
D |
$84.39 |
$105,741 |
D/D |
(1,253) |
43,259 |
0 |
- |
|
| ALKS |
Alkermes Plc |
Director and CEO, Alkermes plc |
• • – |
2018-05-08 |
4 |
OE |
$12.29 |
$614,500 |
D/D |
50,000 |
716,352 |
0 |
- |
|
| ALKS |
Alkermes Plc |
Director and CEO, Alkermes plc |
• • – |
2018-05-08 |
4 |
AS |
$44.28 |
$2,215,775 |
D/D |
(50,000) |
666,352 |
0 |
- |
|
| ALKS |
Alkermes Plc |
Director and CEO, Alkermes plc |
• • – |
2018-05-15 |
4 |
OE |
$12.29 |
$614,500 |
D/D |
50,000 |
716,352 |
0 |
- |
|
| ALKS |
Alkermes Plc |
Director and CEO, Alkermes plc |
• • – |
2018-05-15 |
4 |
AS |
$46.38 |
$2,319,100 |
D/D |
(50,000) |
666,352 |
0 |
- |
|
| ALKS |
Alkermes Plc |
Director and CEO, Alkermes plc |
• • – |
2018-05-22 |
4 |
AS |
$45.33 |
$909,163 |
D/D |
(20,000) |
666,352 |
0 |
- |
|
| ALKS |
Alkermes Plc |
Director and CEO, Alkermes plc |
• • – |
2018-05-22 |
4 |
OE |
$12.29 |
$245,800 |
D/D |
20,000 |
686,352 |
0 |
- |
|
| NBIX |
Neurocrine Biosciences In... |
Director |
– • – |
2018-10-29 |
4 |
AS |
$107.13 |
$589,237 |
D/D |
(5,500) |
37,759 |
0 |
- |
|
| NBIX |
Neurocrine Biosciences In... |
Director |
– • – |
2018-11-12 |
4 |
AS |
$103.30 |
$425,893 |
D/D |
(4,123) |
33,636 |
0 |
- |
|
| NBIX |
Neurocrine Biosciences In... |
Director |
– • – |
2018-11-26 |
4 |
AS |
$91.37 |
$376,790 |
D/D |
(4,124) |
29,512 |
0 |
- |
|
| ALKS |
Alkermes Plc |
Director and CEO, Alkermes plc |
• • – |
2018-12-07 |
4 |
D |
$34.01 |
$415,738 |
D/D |
(12,224) |
681,628 |
0 |
- |
|
| ALKS |
Alkermes Plc |
Director and CEO, Alkermes plc |
• • – |
2018-12-07 |
4 |
A |
$0.00 |
$0 |
D/D |
27,500 |
693,852 |
0 |
- |
|
| XLRN |
Acceleron Pharma Inc |
Director |
– • – |
2019-01-25 |
4 |
A |
$0.00 |
$0 |
D/D |
1,250 |
32,500 |
0 |
- |
|
257 Records found
|
|
Page 7 of 11 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
